What is Rinri Therapeutics?
Rinri Therapeutics is a private biotechnology company dedicated to pioneering advanced stem cell-based therapeutics aimed at restoring hearing. Established in late 2018 and headquartered in Sheffield, UK, the company is at the forefront of regenerative medicine, seeking to address the significant unmet need in hearing loss treatment. Their work involves developing novel approaches that leverage the regenerative potential of stem cells to repair or replace damaged auditory tissues.
How much funding has Rinri Therapeutics raised?
Rinri Therapeutics has raised a total of $19.4M across 3 funding rounds:
Angel/Seed
$985K
Unspecified
$13.9M
Grant
$4.5M
Angel/Seed (2019): $985K, investors not publicly disclosed
Unspecified (2021): $13.9M led by Boehringer Ingelheim Venture Fund
Grant (2021): $4.5M supported by Innovate UK
Key Investors in Rinri Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in pioneering science aimed at redefining care standards and developing new medicines for patients. The fund focuses on first-in-class, disease-modifying therapeutics across various modalities.
Innovate UK
Innovate UK is an innovation agency that supports business growth and technological advancement. It was established to drive innovation across various sectors within the UK.
What's next for Rinri Therapeutics?
With the recent major strategic investment and substantial overall capital, Rinri Therapeutics is poised for significant advancement in its research and development pipeline. The enterprise-level funding suggests a transition towards scaling operations and potentially moving towards clinical trials. This strategic backing will likely accelerate the company's efforts to bring its innovative stem cell therapies from the laboratory to patients, marking a critical phase in its growth trajectory and its mission to combat hearing impairment.
See full Rinri Therapeutics company page
